Previously, (Youn et al. 2023) demonstrated that marine derived bioactive compounds target multiple AD related pathways, including AChE inhibition, suppression of amyloid‐beta aggregation, and NF‐κB signaling modulation to overcome the AD related pathology. The gene discussed is NFKB1; the disease is Alzheimer disease.